“We have developed a 2030 Pharmaceutical Action Plan/Continental Vision for Africa. This project advances President Biden’s Build Back Better World (B3W) Initiative by bolstering global health infrastructure.” “Supporting the global community’s continued response to the COVID-19 pandemic, strengthening health security, and improving health systems in developing countries are top priorities for DFC. “The United States is proud to collaborate on this effort to expand manufacturing capacity for COVID-19 and other critical vaccines in Africa in order to improve healthcare on the continent,” said DFC CEO Scott Nathan.
We are pleased that the consortium of funders is willing to work with Biovac to create sustainable African vaccine manufacturing, not only to respond to the current pandemic, but also to much needed routine vaccines and future pandemic vaccines as well,” said Biovac CFO Craig Mitchell. “COVID-19 has proven that a more geographical spread of vaccine manufacturing is much needed globally, with the African continent having the least number of vaccine manufacturers. International Development Finance Corporation (DFC), European Investment Bank (EIB), the European Union Delegation to South Africa, International Finance Corporation (IFC), the Industrial Development Corporation of South Africa (IDC), and the French development finance institution Proparco. The consortium partners include the African Development Bank (AfDB), CDC Group – UK’s development finance institution which is soon to be renamed British International Investment, the German development finance institution DEG, the U.S. The consortium partners will aim to support Biovac in this future manufacturing plant capacity and vaccine pipeline expansion. To realize the expansion and increased local vaccine manufacturing capacity on the African continent, Biovac will need to raise around $150 million (ZAR2.3 billion). This expansion is aligned with the UN Sustainable Development (SDG) Goal 3 on Good Health and Well-being by improving access to safe, effective, quality and affordable essential medicines and vaccines and UN SDGs 8 and 9 on improving economic opportunities and upgrading technological capabilities of the pharmaceutical manufacturing sector in Africa. This will bolster the global response to COVID-19 and advance long-term health security throughout the African continent. Biovac has also entered into an agreement with Pfizer in July 2021 with the goal to manufacture up to 100 million doses of the Pfizer-BioNTech COVID-19 vaccine for use exclusively in Africa.īiovac aims to expand its vaccine manufacturing capacity in Africa initially through its current activities related to the production of Pfizer-BioNTech’s COVID-19 vaccine and subsequently for much needed routine vaccines as well. Partners include AfDB, CDC Group, DEG, DFC, EIB, IFC, Proparco, the European Union Delegation to South Africa, and the Industrial Development Corporation of South Africa (IDC).ĬAPE TOWN, South Africa – To support South Africa and the African continent increase vaccine manufacturing capacity and reduce reliance on imports, a consortium of nine development and finance institutions have today announced a partnership with Biovac in Cape Town, South Africa to support Biovac’s vaccine manufacturing expansion.īiovac, a bio-pharmaceutical company and established vaccine manufacturer based in South Africa, is part of a consortium of organizations that has partnered with the World Health Organization (WHO) and its COVAX partners to establish the first COVID-19 mRNA vaccine technology transfer hub in South Africa. Biovac to raise around $150 million (ZAR2.3 billion) to boost increased local vaccine manufacturing capacity across the African continent.
Consortium of nine development partners to support Biovac’s expansion of its existing vaccine manufacturing plant capacity, and enable the production of Pfizer-BioNTech’s COVID-19 vaccine and other vaccines.
0 kommentar(er)
